ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) Stock Price Pass Below 50-Day Moving Average – Here’s What Happened

ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB)’s share price crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $84.30 and traded as low as $83.36. ProShares Ultra Nasdaq Biotechnology shares last traded at $83.88, with a volume of 3,351 shares changing hands.

ProShares Ultra Nasdaq Biotechnology Trading Down 1.0%

The company’s 50 day moving average is $84.27 and its 200 day moving average is $74.75. The stock has a market capitalization of $82.57 million, a price-to-earnings ratio of 20.68 and a beta of 1.38.

ProShares Ultra Nasdaq Biotechnology Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Wednesday, December 24th were issued a dividend of $0.1346 per share. The ex-dividend date of this dividend was Wednesday, December 24th. This represents a $0.54 annualized dividend and a dividend yield of 0.7%.

Institutional Trading of ProShares Ultra Nasdaq Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in BIB. Franklin Resources Inc. purchased a new position in ProShares Ultra Nasdaq Biotechnology during the 2nd quarter worth approximately $32,000. Citadel Advisors LLC purchased a new position in shares of ProShares Ultra Nasdaq Biotechnology during the third quarter worth approximately $307,000. Kaizen Financial Strategies acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology in the 4th quarter valued at $424,000. Palumbo Wealth Management LLC acquired a new position in shares of ProShares Ultra Nasdaq Biotechnology in the 3rd quarter valued at $766,000. Finally, Laurel Wealth Advisors LLC raised its position in ProShares Ultra Nasdaq Biotechnology by 4,481.0% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 13,743 shares of the exchange traded fund’s stock valued at $630,000 after purchasing an additional 13,443 shares during the last quarter.

ProShares Ultra Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day.